CliffBio
small molecule

GRALISE

GABAPENTIN

Loss of exclusivity—loss of exclusivity
CompanyAlmatica Pharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameGRALISE
Active ingredientGABAPENTIN
Strength900MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalApril 2023
Marketing statusRX

More from Almatica Pharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.